Why is Nureca falling/rising?

Short-Term Price Momentum and Market Outperformance

The stock has demonstrated notable short-term strength, gaining 7.55% over the past week compared to a marginal 0.10% rise in the Sensex. This recent rally includes a three-day consecutive gain, during which Nureca’s shares appreciated by 10.93%. On 27-Nov, the stock opened with a gap up of 4.26% and reached an intraday high of ₹280.75, outperforming its sector, Medical Equipment/Supplies/Accessories, which itself rose by 2.93%. Furthermore, Nureca is trading above all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—signalling a strong technical uptrend.

Robust Quarterly Financial Performance

Underlying this price appreciation is the company’s very positive quarterly performance reported in September 2025. Nureca posted a remarkable net profit growth of 348.15%, with net sales reaching a quarterly high of ₹37.74 crores. Operating profit before depreciation, interest, and taxes (PBDIT) also hit a peak at ₹3.28 crores, while the operating profit margin relative to net sales improved to 8.69%, the highest recorded for the company. This consistent positive earnings trajectory over the last three quarters has evidently bolstered investor confidence.

Promoter Confidence Boosts Market Sentiment

Adding to the positive sentiment is the increased promoter stake in Nureca, which rose by 0.64% over the previous quarter, bringing their total holding to 64.97%. Such a move is often interpreted as a strong vote of confidence by insiders in the company’s future prospects, encouraging other investors to follow suit. This rising investor participation is further evidenced by a dramatic surge in delivery volume on 26 Nov, which increased by over 2000% compared to the five-day average, signalling heightened market interest and liquidity.

Long-Term Challenges Temper Enthusiasm

Despite the recent gains, Nureca’s longer-term fundamentals remain a concern. The company has experienced a steep decline in operating profits over the past five years, with a negative compound annual growth rate (CAGR) of 143.07%. Its average return on equity stands at a modest 5.62%, indicating limited profitability relative to shareholders’ funds. Additionally, the stock has underperformed the broader market consistently, delivering a negative 1.18% return over the last year and a significant 50.22% loss over three years, while the Sensex and BSE500 indices have posted robust gains in the same periods.

Valuation and Risk Considerations

Investors should also note that Nureca’s stock is considered risky relative to its historical valuations, partly due to negative EBITDA figures. Although profits have surged by nearly 247% over the past year, the stock’s price-to-earnings-to-growth (PEG) ratio remains low at 0.3, suggesting that the market may be undervaluing its growth potential or pricing in significant risk. This dichotomy between short-term earnings improvement and weak long-term fundamentals presents a complex investment case.

Conclusion: A Stock on the Rise Amid Mixed Signals

In summary, Nureca’s share price rise on 27-Nov is primarily driven by strong quarterly earnings, increased promoter confidence, and positive technical indicators. The stock’s recent outperformance relative to its sector and benchmark indices reflects renewed investor interest. However, the company’s weak long-term profitability and consistent underperformance against benchmarks caution investors to weigh these gains against inherent risks. For those considering exposure to Nureca, monitoring upcoming financial results and sector developments will be crucial to assess whether the current momentum can be sustained.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →